Current

What services do we provide?

CURRENT INVESTMENTS

The below list includes all current portfolio companies managed by Fund+

Minoryx is a clinical stage biotech company leading the development of new therapies for orphan CNS diseases with a high unmet medical need. The company’s lead program is MIN-102, currently in clinical trials for X-linked Adrenoleukodystrophy and Friedreich’s Ataxia.

The Minoryx team is made up of a group of experts with several decades of experience in biotech and pharma. The company is backed by a syndicate of experienced investors and has support from a network of other organizations. Minoryx was founded in 2011 and has operations both in Spain (Mataró, Barcelona) and Belgium (Charleroi Brussels South Biopark).

Website

Aelin Therapeutics is founded by VIB and its partner universities KU Leuven, VUB and UGent, based on the groundbreaking work of renowned structural biologists Prof Joost Schymkowitz and Prof Frederic Rousseau. Using the Pept-in™ platform technology, Aelin can create a complete new class of antibiotics and first-in-class therapeutics against high-value undruggable human targets. The technology harnesses the power of protein aggregation to specifically induce functional knockdown of a target protein.

The company is based on a very comprehensive preclinical Proof of Concept data package illustrating different applications of the technology such as in bacteria and cancer cells, but also in fungi, viruses and plant cells, with publications in high impact journals including Science.

Website

Horama is a clinical-stage biotech company that develops gene-therapy treatments, based on recombinant adeno-associated virus (rAAV) vectors, targeting rare inherited retinal diseases.

Horama was founded in 2014 by a complementary team of world-renown academic researchers who conducted, in 2011, one of the first clinical trials of gene therapy applied to ophthalmology in France, including: Philippe Moullier, Christian Hamel (1955-2017) and Vasiliki Kalatzis, from the French National Institute of Health and Medical Research (INSERM); and Michel Weber and Guylène Le Meur, from the Nantes University Hospital in France.

Website

Immunic AG is a clinical stage biotech company founded in 2016 and focused on the development of immune modulators to block Th17 and Th1-mediated immune and autoimmune responses. Immunic is based in the Munich biotech hub Martinsried, Germany, and has subsidiaries in Halle/Saale, Germany, and Melbourne, Australia.

The company currently develops three products for the treatment of chronic inflammatory and autoimmune diseases including e.g. inflammatory bowel disease, multiple sclerosis and psoriasis.

  • Immunic’s lead development program, IMU-838, is currently in phase 2 clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with additional phase 2 trials in Crohn’s disease and primary sclerosing cholangitis planned for 2019.
  • IMU-935 is a best-in-class inverse agonist of the nuclear receptor RORγt and currently in preclinical development.
  • IMU-856 is a newly developed and orally available small molecule aiming at a yet undisclosed target and currently in preclinical testing.

Website

OCTIMET Oncology NV acts as a translational accelerator, focusing on creating value for investors and patients by providing rapid clinical proof of concept for cancer therapies through innovative clinical development strategies and patient centered biomarker approaches.

OCTIMET was set-up in 2016 and is run by a highly experienced management team. The current focus is on its clinical stage asset OMO-1, a highly selective small molecule MET inhibitor that will be developed with specific biomarkers, whilst an additional late pre-clinical stage oncology asset OMO-2 will also enter the portfolio.

Website

eTheRNA Immunotherapies is a clinical-stage biotech company applying mRNA- based immunotherapies to the treatment of cancer.

eTheRNA’s goal is to commercialize these immunotherapies to deliver long lasting clinical remission to cancer patients.

The company is a spin-off of the ‘Vrije Universiteit Brussel’ (VUB), based on proprietary research by Prof Kris Thielemans, and is backed by a strong international syndicate of investors.

eTheRNA’s TriMix platform comprises three mRNAs encoding proteins (caTLR4, CD40L and CD70) that work to deliver optimal activation of dendritic cells. These cells behave as immune response mediators and mobilize the immune system to attack cancer cells through inducing powerful T-cell responses.

Website

Novadip Biosciences, a biomedical spin-off company from the University of Louvain (UCL, Belgium) and its academic hospital, (Cliniques universitaires Saint-Luc), is developing innovative solutions for critical tissue reconstruction. Using its proprietary technology platform for tissue engineering and manufacturing, Novadip is addressing the need for critical size bone and skin reconstruction in patients who currently have limited or no effective treatment options.

Novadip’s first product is being tested in a phase 1/2a clinical trial in spinal fusion patients. A second product, specifically designed for large bone defects, is currently enrolling patients with non-healing bone fractures (bone non-union) in a phase 1/2a clinical trial.

Novadip is also developing a regenerative skin product aimed at reconstruction of large skin defects or grafts and is using its technology platform to develop “off-the-shelf” products to address additional, larger clinical indications.

Website

iTeos Therapeutics is a private biotechnology company targeting metabolism of the tumor microenvironment to develop small molecule immunomodulators for cancer treatments. iTeos is building its activities upon the unparalleled expertise of the Ludwig Cancer Research (LICR) – a world-class Research Institute in the fields of tumor immunology, therapeutic cancer vaccines, cancer biology and translational medicine in cancer.

iTeos endeavours to develop small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standard of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints (e.g. anti-CTLA4, anti-PD1 and anti-PDL1 antibodies).

Based in Gosselies, Belgium iTeos is a private company launched in 2012 as a spin-off of the Ludwig Cancer Research (LICR) and the de Duve Institute at the Université catholique de Louvain. iTeos raised €9,1M in 2012 from private investors, including LICR, Life Sciences Research Partners, Vives II, Hunza Ventures SCA, several high net worth individuals and from a Walloon government grant.

Website

Promethera® Biosciences is a Belgian pharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatment based on allogeneic adult stem cell technology.

Promethera® Biosciences’ mission is to discover, develop, and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells harvested from healthy human livers.

Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type, the Heterologous Human Adult Liver Progenitor Cell (HHALPC):

  • Promethera® HepaStem, a unique cell therapy product, to treat severe diseases of the liver affecting children and adults. The innovation resides in both the simplicity of the treatment, which doesn’t require radical surgery (compared to liver transplantation), and in the wide variety of liver diseases that can be addressed with the same product.
  • Promethera® H2Screen and H3Screen, a unique cell model for the pharmaceutical industry to mimic metabolism and detoxification of new drugs by the human liver. The cell model is designed for the discovery and pre-clinical evaluation of new chemical entities.

Website

EPICS Therapeutics is a Belgian drug discovery and development company, incorporated in 2018 as a ULB spin-off, based on proprietary research performed in the lab of Prof Francois Fuks. EPICS develops innovative small molecules acting through novel RNA epigenetic targets for cancer treatment.

Recent discovery efforts targeting DNA and histone modifications have already given some of the most promising drugs to treat cancer. Modifications to RNA are much more common than to DNA, further highlighting the huge potential of using RNA epigenetics for therapeutic applications. By targeting RNA modifications, EPICS aims to translate science into life-changing therapies for patients.

Website

Confo Therapeutics is a drug discovery company building a unique pipeline of GPCR targeted therapeutics addressing unmet medical needs. The company was founded in 2015 as a spin-off from the Vrije Universiteit Brussel and VIB and capitalizes on the ConfoBody technology developed by Prof. Jan Steyaert.

Confobodies are camel signle domein antibodies that stabilize distinct druggable conformers of flexible protein targets and reveal previously inaccessible structural features. Confo Therapeutics uses these ConfoBody-stabilized functional conformations of GPCRs as a superior starting point for drug discovery empowering the discovery of novel agonists for better therapeutic intervention.

Website

EyeD Pharma was created in 2012 on the initiative of Professor Jean-Marie Rakic (Head of the Ophthalmology Department at Liège University Hospital, CHU), together with a group of other ophthalmologists and a few private investors.
Currently, the company is developing an innovative drug delivery system based on a controlled-release intraocular implant.

EyeD Pharma is initially focusing on the treatment of glaucoma, an eye disease that mainly affects people over the age of 45. Traditionally, glaucoma is treated by administering eye drops every day for the rest of the patient’s life. This drug treatment is very burdensome and causes local side effects, such as eye irritation. If the patient is not treated or is inconsistent in taking the treatment, glaucoma is accompanied by irreversible degeneration of the optic nerve, resulting in loss of vision (second biggest cause of blindness in developed countries).

Website